Thoenes M, Bramlage P, Zhong S, et al - Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract, 2012, 2012, 925046.
Keith C Ferdinand. - Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease. Curr Med Res Opin, 2005, 21, 1091-1097.
Jackson R, Lawes CMM, Bennett DA, et al - Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet, 2005, 365, 434-441.
Scheen AJ, Krzesinski JM - Combinaison fixe perindopril-amlodipine (Coveram®) dans le traitement de l'hypertension artérielle et de l'insuffisance coronaire. Rev Med Liege, 2009, 64, 223-227.
Scheen AJ, Lancellotti P, Krzesinski JM - Combinaison fixe perindopril-indapamide-amlodipine (Triplixam®) pour le traitement de l'hypertension artérielle. Rev Med Liege, 2014, 69, 565-570.
Sever P, Dahlöf B, Poulter N, et al - ASCOT Steering Committee Members. Potential synergy between lipidlowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J, 2006, 27, 2982-2988.
Lim SS, Vos T, Flaxman AD, et al - A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380, 2224-2260.
Mancia G, Fagard R, Narkiewicz K, et al - 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Pressure, 2013, 22, 193-278.
Bertrand ME, Vlachopoulos C, Mourad JJ - Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine. Am J Cardiovasc Drugs, 2016, 16, 241-253.
Egan BM, Li J, Qanungo S, et al - Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010. Circulation, 2013, 128, 29-41.
Chapman RH, Benner JS, Petrilla AA, et al - Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med, 2005, 23, 165, 1147-1152.
Chowdhury R, Khan H, Heydon E, et al - Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J, 2013, 34, 2940-2948.
Scheen AJ. - Pharma-clinics. Le médicament du mois. L'atorvastatine (Lipitor®). Rev Med Liege, 1998, 53, 374-377.
Cilla DD Jr, Gibson DM, Whitfield LR, et al - Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol, 1996, 36, 604-609.
Plakogiannis R, Cohen H, Taft D. - Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm, 2005, 62, 2491-2494.
Ghiadoni L. - Perindopril for the treatment of hypertension. Expert Opin Pharmacother, 2011, 12, 1633-1642.
Résumé des caractéristiques du produit Lipertance®. http://bijsluiters.fagg-afmps.be/registrationSearchServlet?key=BE482942&leafletType=rcp
Law MR, Wald NJ, Rudnicka AR - Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003, 326, 1423.
Hatala R, Pella D, Hatalová K, et al. - Optimization of blood pressure treatment with fixed-combination perindopril/amlodipine in patients with arterial hypertension. Clin Drug Investig, 2012, 32, 603-612.
Jamerson K, Weber MA, Bakris GL, et al - ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med, 2008, 359, 2417-2428.
Huffman MD. - The polypill: from promise to pragmatism. PLoS Med, 2015, 12, e1001862
Scheen AJ, Lefèbvre PJ, Kulbertus H. - Prévention cardio-vasculaire: la «polypill», une solution pour vaincre l'inertie clinique et le manque d'observance? Rev Med Liege, 2010, 65, 267-272.
